IRTC IRhythm Technologies Inc.

iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence

iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company’s Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in support of the company’s global expansion plans.

“We are very pleased to welcome Brice and Reyna to our expanded leadership team as we continue to execute upon our vision of building iRhythm into a market leader in the digital healthcare space,” said Quentin Blackford, iRhythm’s President and CEO. “Brice is a veteran executive who brings a wealth of experience building finance teams and guiding organizations through operational transformations. His focus on operational excellence with a disciplined and rigorous approach to financial management and strategic development will position us well for the future. With the addition of Brice into the CFO role, this will allow Doug to focus on the continued improvement of our operational functions that he will continue to lead. Reyna is a seasoned HR executive with over 25 years of experience in building human resource teams, implementing talent development programs, and transforming organizations to operate strategically, globally and efficiently. We look forward to these two successful individuals joining our team to help lead the organization through significant growth with a focus on operational effectiveness and efficiency.”

About Mr. Bobzien

Brice Bobzien most recently served as the Senior Vice President, Finance & Investor Relations of Dexcom, Inc., where he was responsible for global financial planning and analysis, investor relations, operations accounting, and global pricing strategy. Brice played an instrumental role in driving revenue growth initiatives that resulted in the company growing from $700 million to forecasted revenues of approximately $2.9 billion for fiscal year 2022. This growth included the scaling of the company’s global footprint, expanding beyond the United States and into more than 50 countries. During this time, Brice transformed the finance team into a world class organization designed to foster revenue growth and operational discipline. Brice’s track record includes more than 20 years of experience and increasing responsibility at leading medical device companies, including Zimmer Holdings, Inc., NuVasive, Inc. and Dexcom, Inc. Prior to these roles, Brice began his career in public accounting. Brice earned his Bachelor of Science degree in Business Administration from Indiana University, Fort Wayne, and is a Certified Public Accountant (non-practicing) in the state of Indiana.

About Ms. Fernandez

Reyna Fernandez most recently served as Chief Human Resources Officer at Intersect ENT, Inc., where she was responsible for envisioning and implementing human resources strategies to support the company in becoming an integrated, world-class player in the therapeutics space. Reyna was instrumental in driving the continued growth of Intersect ENT through best-in-class talent acquisition, organizational effectiveness and human capital management functions. During her tenure with the company, she partnered with the CEO and executive leadership to create a performance culture focused on growth and operational excellence, transformed the HR organization to scale globally in line with business objectives, and worked strategically with the board of directors to align on compensation practices. Reyna brings global experience from her roles with Endologix, Inc., Canon Medical Systems USA, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. Reyna earned her Master of Social Administration from Columbia University and a Bachelor of Arts degree in Cultural Anthropology from Haverford College in Pennsylvania.

About iRhythm Technologies, Inc.

iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based on current assumptions that involve risks and uncertainties, and actual outcomes and results could differ materially from those anticipated. The risks and uncertainties that may cause actual results to differ materially from current expectations, many of which are beyond our control, include risks more fully described in iRhythm’s Quarterly Report on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on May 6, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except as required by law, iRhythm assumes no obligation to update any such forward-looking statement after the date of this release.

Investor Relations Contact

Stephanie Zhadkevich

(919) 452-5430

iRhythm Media Contact

Morgan Mathis

(310) 528-6306



EN
25/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

 PRESS RELEASE

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlig...

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to tho...

 PRESS RELEASE

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期...

第18回アジア太平洋不整脈学会学術大会(APHRS2025)で発表された新たなデータにより アジア人集団におけるiRhythm社のZio長期連続モニタリングの性能が明らかに iRhythm Technologies, Inc.は、アジア太平洋不整脈学会学術大会(APHRS2025)と第71回日本不整脈心電学会学術大会(JHRS2025)の合同学術集会において新しいデータを発表しました。40万人を超える患者を対象とした大規模解析 1 により、長期間の心電図(ECG)モニタリングの性能の一貫性と一般化可能性が裏付けられました。アジア人患者(コホートの3.4%)における中央値の装着時間および解析可能時間は非アジア人患者と同等であり、この結果は既発表のCAMELOT研究2 およびAVALON研究3 で報告されたZio LTCMの性能と一致していました。 サンフランシスコ, Nov. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) は2025年11月12日から15日まで日本・横浜で開催された第18回アジア太平洋不整脈学会(APHRS)/第71回日本不整脈心電学会学術大会(JHRS2025)合同学術集会において、口頭発表セッションで新たなデータを発表したと明らかにしました。 河田 宏医師の主導のもと、研究チームは米国の大規模患者コホートを対...

 PRESS RELEASE

iRhythm Technologies Announces Publication of Large-Scale Study in Hea...

iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025 Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio® long-term continuous monitoring (LTCM)– even in patients with frequent (i.e., daily) symptoms1Data from more than 742,000 patients presented at the American Heart Association (AHA) Scientific Sessions 2025 confirm that at-home self-application and activation of Zio 14-day patc...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wolfe Research 2025 Healthcare Conference on Tuesday, November 18, 2025, at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time)Jefferies 2025 Global Healthcare Conference on Thursday, November 20, 2025, at 9:30 a.m. Greenwich Mean Time (1:30...

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 8,000 shares at 207.440USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch